Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner.
Int J Obes (Lond) · 2012
Last updated 2026-05-28In a study on rats, researchers found that two signals in the brain—one triggered by leptin and another by GLP-1—work together to reduce food intake and body weight in a way that adds up. When both signals were activated at the same time, food intake dropped by about 33% with leptin alone, and even further when combined with a GLP-1 drug called exendin-4. Blocking the GLP-1 signal weakened the effect of leptin, showing these signals naturally interact to control eating.
AI summary of the abstract below.
| Journal | Int J Obes (Lond), 2012 |
|---|---|
| Citations | 71 |
| Relative citation ratio | 2.13 |
| NIH percentile | 75 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
BACKGROUND: The physiological control of feeding behavior involves modulation of the intake inhibitory effects of gastrointestinal satiation signaling via endogenous hindbrain leptin receptor (LepR) and glucagon-like-peptide-1 receptor (GLP-1R) activation.
DESIGN AND RESULTS: Using a variety of dose-combinations of hindbrain delivered (4th intracerebroventricular; i.c.v.) leptin and the GLP-1R agonist exendin-4, experiments demonstrate that hindbrain LepR and GLP-1R signaling interact to control food intake and body weight in an additive manner. In addition, the maximum intake suppressive response that could be achieved by 4th i.c.v. leptin alone in non-obese rats (∼33%) was shown to be further suppressed when exendin-4 was co-administered. Importantly, it was determined that the interaction between hindbrain LepR signaling and GLP-1R signaling is relevant to endogenous food intake control, as hindbrain GLP-1R blockade by the selective antagonist exendin-(9-39) attenuated the intake inhibitory effects of hindbrain leptin delivery.
CONCLUSIONS: Collectively, the findings reported here show that hindbrain LepR and GLP-1R activation interact in at least an additive manner to control food intake and body weight. As evidence is accumulating that combination pharmacotherapies offer greater sustained food intake and body weight suppression in obese individuals when compared with mono-drug therapies or lifestyle modifications alone, these findings highlight the need for further examination of combined central nervous system GLP-1R and LepR signaling as a potential drug target for obesity treatment.
Verbatim abstract via PubMed 22249232 ↗